WILMINGTON, Del., Dec. 05, 2016 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violation and breach of fiduciary duty claims against the Board of Directors of Immunomedics, Inc. (“Immunomedics” or the “Company”).
If you own shares of Immunomedics and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/immunomedics-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – https://www.linkedin.com/company/andrews-&-springer-llc , Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Call Toll Free: 1-800-423-6013


RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Britain Courts Anthropic Amid US Defense Department Dispute
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 



